Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News
  • Published:

Alnylam launches era of RNAi drugs

This article has been updated

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Change history

  • 06 September 2018

    In the version of this article initially published, the company's name was given as Alnylam Therapeutics instead of Alnylam Pharmaceuticals in the first sentence and as Alynlam instead of Alnylam in the image caption. The error has been corrected in the HTML and PDF versions of the article.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Garber, K. Alnylam launches era of RNAi drugs. Nat Biotechnol 36, 777–778 (2018). https://doi.org/10.1038/nbt0918-777

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0918-777

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing